WallStreetZenWallStreetZen

NASDAQ: NKTR
Nektar Therapeutics Stock

$0.62+0.02 (+3.33%)
Updated Jun 2, 2023
NKTR Price
$0.62
Fair Value Price
$1.09
Market Cap
$117.14M
52 Week Low
$0.58
52 Week High
$5.18
P/E
-0.28x
P/B
0.49x
P/S
1.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$88.83M
Earnings
-$414.82M
Gross Margin
73.7%
Operating Margin
-432.31%
Profit Margin
-467%
Debt to Equity
1.33
Operating Cash Flow
-$267M
Beta
1.14
Next Earnings
Aug 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

NKTR Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NKTR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NKTR ($0.62) is undervalued by 43.11% relative to our estimate of its Fair Value price of $1.09 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NKTR ($0.62) is significantly undervalued by 43.11% relative to our estimate of its Fair Value price of $1.09 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NKTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NKTR due diligence checks available for Premium users.

Be the first to know about important NKTR news, forecast changes, insider trades & much more!

NKTR News

Valuation

NKTR fair value

Fair Value of NKTR stock based on Discounted Cash Flow (DCF)
Price
$0.62
Fair Value
$1.09
Undervalued by
43.01%
NKTR ($0.62) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NKTR ($0.62) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NKTR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NKTR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.28x
Industry
11.51x
Market
52.74x

NKTR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
5.19x
NKTR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NKTR's financial health

Profit margin

Revenue
$21.6M
Net Income
-$137.0M
Profit Margin
-634.5%
NKTR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NKTR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$561.7M
Liabilities
$320.9M
Debt to equity
1.33
NKTR's short-term assets ($491.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKTR's short-term assets ($491.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKTR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NKTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$51.9M
Investing
$40.6M
Financing
$0.0
NKTR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NKTR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NKTR$117.14M+3.00%-0.28x0.49x
PRDS$116.64M+1.07%-1.19x0.71x
CDTX$117.93M-0.76%-7.28x4.39x
ATOS$119.15M+2.06%-4.28x1.05x
CAPR$114.98M0.00%-3.89x18.53x

Nektar Therapeutics Stock FAQ

What is Nektar Therapeutics's quote symbol?

(NASDAQ: NKTR) Nektar Therapeutics trades on the NASDAQ under the ticker symbol NKTR. Nektar Therapeutics stock quotes can also be displayed as NASDAQ: NKTR.

If you're new to stock investing, here's how to buy Nektar Therapeutics stock.

What is the 52 week high and low for Nektar Therapeutics (NASDAQ: NKTR)?

(NASDAQ: NKTR) Nektar Therapeutics's 52-week high was $5.18, and its 52-week low was $0.58. It is currently -88.05% from its 52-week high and 6.72% from its 52-week low.

How much is Nektar Therapeutics stock worth today?

(NASDAQ: NKTR) Nektar Therapeutics currently has 189,235,157 outstanding shares. With Nektar Therapeutics stock trading at $0.62 per share, the total value of Nektar Therapeutics stock (market capitalization) is $117.14M.

Nektar Therapeutics stock was originally listed at a price of $13.00 in Dec 31, 1997. If you had invested in Nektar Therapeutics stock at $13.00, your return over the last 25 years would have been -95.24%, for an annualized return of -11.47% (not including any dividends or dividend reinvestments).

How much is Nektar Therapeutics's stock price per share?

(NASDAQ: NKTR) Nektar Therapeutics stock price per share is $0.62 today (as of Jun 2, 2023).

What is Nektar Therapeutics's Market Cap?

(NASDAQ: NKTR) Nektar Therapeutics's market cap is $117.14M, as of Jun 3, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nektar Therapeutics's market cap is calculated by multiplying NKTR's current stock price of $0.62 by NKTR's total outstanding shares of 189,235,157.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.